Search research articles
Contact Us
Filters
Showing results (261-270 of 281) with videos related to
Page
of 29
Sort By:
Circulation
|
March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators
S G Goodman, A Langer, A M Ross, et al.
Journal of Internal Medicine
|
September 30, 2017
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease
E Hagström, F Norlund, A Stebbins, et al.
The American Journal of Cardiology
|
May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries
J Hochrein, F Sun, K S Pieper, et al.
Circulation
|
June 20, 2001
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
L K Newby, E M Ohman, R H Christenson, et al.
Circulation
|
August 16, 2000
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
R A Harrington, P W Armstrong, C Graffagnino, et al.
Circulation
|
November 3, 1998
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
L K Newby, R H Christenson, E M Ohman, et al.
Journal of the American College of Cardiology
|
July 14, 2001
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network
P Kaul, Y Fu, W C Chang, et al.
The New England Journal of Medicine
|
October 31, 1996
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators
E M Ohman, P W Armstrong, R H Christenson, et al.
The American Journal of Cardiology
|
December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
M T Roe, C B Granger, J A Puma, et al.
The American Journal of Cardiology
|
June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)
A Barbagelata, R M Califf, E B Sgarbossa, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 281) with videos related to
Sort By:
Page
of 29
Circulation
|
March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators
S G Goodman, A Langer, A M Ross, et al.
Journal of Internal Medicine
|
September 30, 2017
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease
E Hagström, F Norlund, A Stebbins, et al.
The American Journal of Cardiology
|
May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries
J Hochrein, F Sun, K S Pieper, et al.
Circulation
|
June 20, 2001
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
L K Newby, E M Ohman, R H Christenson, et al.
Circulation
|
August 16, 2000
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
R A Harrington, P W Armstrong, C Graffagnino, et al.
Circulation
|
November 3, 1998
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
L K Newby, R H Christenson, E M Ohman, et al.
Journal of the American College of Cardiology
|
July 14, 2001
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network
P Kaul, Y Fu, W C Chang, et al.
The New England Journal of Medicine
|
October 31, 1996
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators
E M Ohman, P W Armstrong, R H Christenson, et al.
The American Journal of Cardiology
|
December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
M T Roe, C B Granger, J A Puma, et al.
The American Journal of Cardiology
|
June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)
A Barbagelata, R M Califf, E B Sgarbossa, et al.
Page
of 29